1. Home
  2. AXR vs AGEN Comparison

AXR vs AGEN Comparison

Compare AXR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMREP Corporation

AXR

AMREP Corporation

HOLD

Current Price

$21.74

Market Cap

127.3M

Sector

Real Estate

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.34

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXR
AGEN
Founded
1961
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.3M
126.2M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
AXR
AGEN
Price
$21.74
$3.34
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
5.2K
983.6K
Earning Date
03-06-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.95
N/A
Revenue
$45,947,000.00
$106,829,000.00
Revenue This Year
$12.43
$23.68
Revenue Next Year
$4.48
$23.17
P/E Ratio
$11.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.60
$1.38
52 Week High
$34.00
$7.34

Technical Indicators

Market Signals
Indicator
AXR
AGEN
Relative Strength Index (RSI) 66.97 41.53
Support Level $21.27 $3.01
Resistance Level $21.74 $4.87
Average True Range (ATR) 0.51 0.36
MACD 0.38 0.05
Stochastic Oscillator 100.00 15.95

Price Performance

Historical Comparison
AXR
AGEN

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: